Lv4
506 积分 2022-11-12 加入
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
6小时前
已完结
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
6小时前
已完结
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
18天前
已完结
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
1个月前
已完结
Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
1个月前
已完结
EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ
2个月前
已完结
Simvastatin Enhanced Anti-tumor Effects of Bevacizumab against Lung AdenocarcinomaA549 Cells via Abating HIF-1α-Wnt/β-Catenin Signaling Pathway
4个月前
已完结
Cholesterol depletion decreases adhesion of non-small cell lung cancer cells to E-selectin
4个月前
已完结
Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9
4个月前
已完结
The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms
4个月前
已完结
皖公网安备34019202002308
